Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose

doi:10.1126/science.abh1282

GSTDTAP > 气候变化

DOI	10.1126/science.abh1282
	Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
	Catherine J. Reynolds; Corinna Pade; Joseph M. Gibbons; David K. Butler; Ashley D. Otter; Katia Menacho; Marianna Fontana; Angelique Smit; Jane E. Sackville-West; Teresa Cutino-Moguel; Mala K. Maini; Benjamin Chain; Mahdad Noursadeghi; UK COVIDsortium Immune Correlates Network‡; Tim Brooks; Amanda Semper; Charlotte Manisty; Thomas A. Treibel; James C. Moon; UK COVIDsortium Investigators‡; Ana M. Valdes; Áine McKnight; Daniel M. Altmann; Rosemary Boyton
	2021-06-25
发表期刊	Science
出版年	2021
英文摘要	During clinical trials of severe acute respiratory syndrome coronavirus 2 vaccines, no one who had survived infection with the virus was tested. A year after the pandemic was declared, vaccination of previously infected persons is a reality. Reynolds et al. address the knowledge gap in a cohort of UK health care workers given the Pfizer/BioNTech vaccine in which half of the participants had experienced natural virus infections early in the pandemic (see the Perspective by Crotty). Genotyping indicated that a genetic component underlies heterogeneity in immune responses to vaccine and to natural infection. After vaccination, naïve individuals developed antibody responses similar to those seen in naturally infected persons, but T cell responses were more limited and sometimes absent. However, antibody and memory responses in individuals vaccinated after infection were substantially boosted to the extent that a single vaccine dose is likely to protect against the more aggressive B.1.1.7 variant. It is possible that the messenger RNA vaccine has an adjuvant effect, biasing responses toward antibody generation. Science , abh1282, this issue p. [1418][1]; see also abj2258, p. [1392][2] Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine rollout has coincided with the spread of variants of concern. We investigated whether single-dose vaccination, with or without prior infection, confers cross-protective immunity to variants. We analyzed T and B cell responses after first-dose vaccination with the Pfizer/BioNTech messenger RNA vaccine BNT162b2 in health care workers (HCW) followed longitudinally, with or without prior Wuhan-Hu-1 SARS-CoV-2 infection. After one dose, individuals with prior infection showed enhanced T cell immunity, antibody-secreting memory B cell response to the spike protein, and neutralizing antibodies effective against variants B.1.1.7 and B.1.351. By comparison, HCW receiving one vaccine dose without prior infection showed reduced immunity against variants. B.1.1.7 and B.1.351 spike mutations resulted in increased, abrogated, or unchanged T cell responses, depending on human leukocyte antigen (HLA) polymorphisms. Single-dose vaccination with BNT162b2 in the context of prior infection with a heterologous variant substantially enhances neutralizing antibody responses against variants. [1]: /lookup/doi/10.1126/science.abh1282 [2]: /lookup/doi/10.1126/science.abj2258
领域	气候变化 ; 资源环境
URL	查看原文
引用统计
文献类型	期刊论文
条目标识符	http://119.78.100.173/C666/handle/2XK7JSWQ/334140
专题	气候变化资源环境科学
推荐引用方式 GB/T 7714	Catherine J. Reynolds,Corinna Pade,Joseph M. Gibbons,et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose[J]. Science,2021.
APA	Catherine J. Reynolds.,Corinna Pade.,Joseph M. Gibbons.,David K. Butler.,Ashley D. Otter.,...&Rosemary Boyton.(2021).Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose.Science.
MLA	Catherine J. Reynolds,et al."Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose".Science (2021).